These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 10376616)

  • 21. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
    N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
    Husson RN; Shirasaka T; Butler KM; Pizzo PA; Mitsuya H
    J Pediatr; 1993 Jul; 123(1):9-16. PubMed ID: 8391570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy: a guide to the most important trials.
    Rutschmann O; Hirschel B
    Schweiz Med Wochenschr; 1997 Mar; 127(11):436-43. PubMed ID: 9098917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
    Kastrissios H; Suárez JR; Katzenstein D; Girard P; Sheiner LB; Blaschke TF
    AIDS; 1998 Dec; 12(17):2295-303. PubMed ID: 9863872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
    Baldeweg T; Catalan J; Gazzard BG
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):34-41. PubMed ID: 9667558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zidovudine plus didanosine in primary HIV-1 infection.
    Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
    Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CPCRA 007: preliminary results of combination antiretroviral study.
    Randall P
    NIAID AIDS Agenda; 1996 Mar; ():2. PubMed ID: 11363796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
    Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final CESARE trial results show continued clinical and survival benefit.
    AIDS Patient Care STDS; 1997 Apr; 11(2):96. PubMed ID: 11361772
    [No Abstract]   [Full Text] [Related]  

  • 40. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.